Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

On May 14, 2026, the Director of the U.S. Patent and Trademark Office designated as precedential a decision denying institution in Magnolia Medical Technologies, Inc. v. Kurin, Inc., IPR2026-00097. But the decision’s broader importance lies in its extended preamble, which explains the Director’s view that AIA proceedings should provide an alternative to district court litigation and that discretionary denial helps preserve that role. The opinion goes on to deny institution in this case based on the petitioner’s use of the same grounds in district court, even though the petitioner was not allowed to present those invalidity theories to a jury. 

The Director’s Policy Reasoning for Discretionary Denials

In Part I of the decision, the Director reviews the legislative history of the AIA and states that, in his view, AIA proceedings have not always been used in a manner consistent with their original purpose. He emphasizes that Congress intended AIA reviews as a “quick and cost-effective alternative” to district court litigation, rather than a tool “for harassment or a means to prevent market entry through repeated litigation and administrative attacks.”

Looking back on fifteen years of AIA practice, the Director suggests that some petitioners have used AIA review in ways he regards as inconsistent with that purpose. He identifies several patterns that, in his view, illustrate the issue, including parallel proceedings involving overlapping or substantially similar art and arguments, repeat challenges to the same patent after unsuccessful prior challenges, and inconsistent positions taken in different forums. The decision also relays the Director’s view that AIA reviews have not frequently been used by small or primarily U.S.-based businesses.

The Director also frames AIA review as implicating broader public-interest considerations. He writes that the factors Congress requires the Office to consider in rulemaking focus on the public interest, rather than only the private interests of the parties before the Board, and he identifies those factors as including the economy, efficient administration of the Office, the Office’s ability to complete AIA reviews in a timely manner, and the integrity of the patent system.

Against that backdrop, the Director maintains that Congress gave the Director broad discretion over institution to advance those objectives. Although the Director notes that “the central purpose of IPRs is to determine whether the patent at issue may have been improvidently granted,” he states that “discretion is afforded to ensure fairness, efficiency, and predictability in patent disputes in a focused inter partes context—as Congress envisioned—as distinct from the broad adjudication of private disputes in district court litigation.”

Finally, the decision points to several recent precedential and informative decisions as illustrations of how the Office has applied these considerations in practice, including decisions addressing a) when examiner error may outweigh factors favoring denial, b) when unexplained claim-construction positions across different forums may support denial, c) how petitions by foreign sovereign entities are treated for discretionary-denial purposes, and d) how the parties’ settled expectations may factor into the analysis.

Why Magnolia’s Petition Was Denied Despite the Lack of a Jury Invalidity Ruling

After setting out his broader policy rationale, the Director turns briefly to the facts of this dispute and explains why, in his view, they warrant discretionary denial. The decision states that Magnolia’s petition presented the same grounds Magnolia had already asserted in the parallel district-court litigation. Although Magnolia’s invalidity theories never reached the jury because the district court excluded its expert testimony, the Director reasons that the absence of a merits ruling on those theories does not warrant institution. Instead, he characterizes the petition as an attempt to take a second bite of the invalidity apple. In his view, this falls outside the intended role of AIA review, regardless of whether the invalidity theory was kept from the jury on substantive or procedural grounds.

Implications for Discretionary-Denial Practice

The decision is significant not only for its denial of institution on these facts, but also because its opening section explains the Director’s opinions on AIA proceedings. Petitioners and patent owners alike should therefore read the decision for its reasoning, not just its result, because the decision lays out policies the Director may consider when reviewing discretionary denial requests. Parties should also watch to see whether Congress, the Federal Circuit, or other courts take up the questions the opinion raises about the scope of the Director’s discretion and the role discretionary denial should play in AIA practice.